Bausch + Lomb parent company Bausch Health is spinning off the eye-care company with an upcoming IPO which will list on the New York Stock Exchange and TSX with the ticker symbol “BLCO”.
This would greatly benefit BLCO stockholders, of which Bausch Health is the largest.
As an 88% owner of BLCO, Bausch Health's value derived from such a sale would be $12.32 billion.
Adding the value of the proceeds from BLCO sale, the Xifaxan cash flows and RemainCo yields a total value of $25.93 billion for Bausch Health.
After subtracting 100% of the Bausch Health debt, that would yield an equity value of $10.49 billion or $28.19 per share.
Persons:
Bausch, Scott Olson, Richard Mulligan, John Paulson, Brett Icahn, Steven Miller, Carl Icahn, BLCO, Goldman Sachs, Bausch Health's, Peers, InMode, Takeda, Gary Hu, Brent Saunders, Ken Squire
Organizations:
Bausch Health, New York Stock Exchange, TSX, U.S . Securities, Exchange, Financial Times, Cooper Companies, BLCO, Products, Takeda Pharmaceuticals, Ironwood Pharmaceuticals, Health, 13D
Locations:
CHICAGO , ILLINOIS, Chicago , Illinois, BLCO